Advertisement

Topics

Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock

20:54 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public o...

Other Sources for this Article

Clovis Oncology, Inc.
Anna Sussman
303.625.5022
asussman@clovisoncology.com
or
Breanna Burkart
303.625.5023
bburkart@clovisoncology.com

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...